These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 28566605)

  • 1. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
    Tokunaga K; Hagino N
    Intern Med; 2017; 56(11):1399-1403. PubMed ID: 28566605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.
    Isoda K; Kotani T; Takeuchi T; Kiboshi T; Hata K; Ishida T; Otani K; Kamimori T; Fujiwara H; Shoda T; Makino S
    Rheumatol Int; 2017 Aug; 37(8):1335-1340. PubMed ID: 28451794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease.
    Nakashima R; Hosono Y; Mimori T
    Lupus; 2016 Jul; 25(8):925-33. PubMed ID: 27252271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
    So H; Wong VTL; Lao VWN; Pang HT; Yip RML
    Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease.
    Wakura R; Matsuda S; Kotani T; Shoda T; Takeuchi T
    Sci Rep; 2020 Sep; 10(1):15692. PubMed ID: 32973255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease.
    Nishina N; Sato S; Masui K; Gono T; Kuwana M
    RMD Open; 2020 Jun; 6(2):. PubMed ID: 32506053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage activation syndrome in adult dermatomyositis: a case-based review.
    Kishida D; Sakaguchi N; Ueno KI; Ushiyama S; Ichikawa T; Yoshinaga T; Shimojima Y; Sekijima Y
    Rheumatol Int; 2020 Jul; 40(7):1151-1162. PubMed ID: 32356114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
    Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S
    Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
    Hozumi H; Fujisawa T; Nakashima R; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.
    Gono T; Tanino Y; Nishikawa A; Kawamata T; Hirai K; Okazaki Y; Shibata Y; Kuwana M
    Int J Rheum Dis; 2019 Aug; 22(8):1582-1586. PubMed ID: 31050194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
    Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
    J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD.
    Mao MM; Xia S; Guo BP; Qian WP; Zheng ZX; Peng XM; Chen RC; Luo Q; Han Q
    Respir Med; 2020 Oct; 172():105983. PubMed ID: 33032789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
    Nandy A; Gaïni S; Sore P
    Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
    [No Abstract]   [Full Text] [Related]  

  • 19. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatomyositis Which Was Double Positive for Anti-MDA5 and Anti-ARS Antibodies That Was Successfully Treated by Intensive Immunosuppressive Therapy.
    Hama S; Higashida-Konishi M; Akiyama M; Shimada T; Takei H; Izumi K; Oshima H; Okano Y
    Intern Med; 2022; 61(7):1085-1091. PubMed ID: 35370250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.